Crossref
Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy
World Journal of Cardiology · 05.11.2026
DOI: 10.4330/wjc.127591 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Cardiology, online erschienen am 05.11.2026. Verfasst von Yi-Ze Qi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Qi, Y., Wang, Z., & Li, X. (2026). Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy. World Journal of Cardiology. https://doi.org/10.4330/wjc.127591
Vancouver
Qi Y, Wang Z, Li X. Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy. World Journal of Cardiology. 2026. doi:10.4330/wjc.127591
BibTeX
@article{Qi2026,
author = {Qi, Yi-Ze and Wang, Zhi-Yuan and Li, Xiang-Dong},
title = {Reframing metabolic dysfunction-associated steatotic liver disease via the cardio-hepatic axis: Phenotype-guided incretin and sodium-glucose cotransporter 2 inhibitor therapy},
journal = {World Journal of Cardiology},
year = {2026},
doi = {10.4330/wjc.127591}
}
EUVIMED